Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone Plus Sintilimab Combined With Standard Neoadjuvant Chemotherapy for Patients With Colorectal Cancer Peritoneal Metastasis
NCT07268677Phase 2Not yet recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of pirfenidone and sintilimab in colorectal cancer (CRC). Primary endpoint: Objective Response Rate at 3 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
pirfenidonesintilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07268677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07268677.